Certara (CERT)
(Delayed Data from NSDQ)
$11.45 USD
-0.13 (-1.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.45 USD
-0.13 (-1.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
by Zacks Equity Research
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
by Zacks Equity Research
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
Best Momentum Stocks to Buy for March 15th
by Zacks Equity Research
CERT, BWMX and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 15, 2023.
New Strong Buy Stocks for March 15th
by Zacks Equity Research
TRIN, CERT, WPP, NUE and BHR have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2023.
Is Certara (CERT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CERT vs. PBYI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERT vs. PBYI: Which Stock Is the Better Value Option?
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 1.53% and 76.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.